michael pellini foundation medicine inc profile  biography  bloomberg feedback michael mike pellini former chief executive officer foundation medicine inc career history chief executive officer foundation medicine inc  presidentcoo clarient inc  vplife sciences safeguard scientifics inc  cooconsultant clarient inc  executive vpcoo lakewood pathology assoc inc  chief executive officer genomics collaborative inc  presidentceo genomics collaborative inc  presidentceo foundation medicine inc unknown ge healthcare unknown show more website wwwfoundationmedicinecom corporate information address  second street cambridge ma  united states phone  fax  web url wwwfoundationmedicinecom from the web personal information education drexel university mba boston college bachelors degree economics thomas jefferson university md show more memberships board memberships cellumen inc board member present foundation medicine inc chairman present foundation medicine inc board member  clarient inc board member  show more other memberships boston college technology council member coriell institute of medical research trustee sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data fmi michael j pellini insider trades for foundation medicine inc bulletin investor alert new york markets open in market snapshot analyst ratings expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close foundation medicine inc nasdaq fmi go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus foundation medicine inc after hours  quotes are delayed by  min jul    pm fmi quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   insider activity individual michael j pellini dr michael j pellini is chairman at foundation medicine inc and membertechnology council at boston college he is on the board of directors at personalized medicine coalition and coriell institute for medical research dr pellini was previously employed as vice presidentlife sciences group by safeguard scientifics inc president  chief operating officer by clarient inc chief operating officer  executive vice president by lakewood pathology associates inc president  chief executive officer by genomics collaborative inc and investment committee member by ben franklin technology partners he also served on the board at cellumen inc and cira discovery sciences inc he received his undergraduate degree from boston college an mba from drexel university and a doctorate degree from sidney kimmel medical college transactions date shares transaction value     disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      award at  per share      award at  per share      acquisition at  per share      award at  per share      disposition at  per share           disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives dr michael j pellini chairman mr troy cox chief executive officer  director dr steven j kafka president  chief operating officer mr jason ryan cfo  principal accounting officer mr tom godden chief information officer dr philip j stephens chief scientific officer dr vincent a miller chief medical officer mr david j daly chief commercial officer  gmclinical oncology ms melanie i nallicheri chief business officer  headbiopharma dr jeffrey s ross medical director  headmolecular diagnostics ms elaine labrecque senior vice presidentoperations mr alexis borisy director dr michael d varney director mr daniel oday director dr sandra j horning director mr mike j nolan senior vice presidentglobal sales mr matt franklin senior vice presidentglobal marketing ms susan t hager svpcorporate communications  government affairs ms kimberly maxwell brown directorinvestor relations mr robert w hesslein senior vice president  general counsel mr michael r dougherty independent director dr krishna yeshwant independent director mr evan jones independent director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest aftse  under pressure as bt pushed lower afrances cac  falls  dropping further in early friday trade abarclays falls  after earnings report abritish airways parent iag rises  after quarterly profit report abritish airways parent iags profit soars agermanys dax opens  lower at  afrances cac  opens  lower at  alinde profit slides on restructuring costs auks ftse  opens  lower at  abarclays swings to loss on africa writedown astoxx europe  opens  lower at  aeurope’s refugee crisis won’t be solved in a distant court asantander profit rises upbeat on banco popular afrench inflation steady in july arotork ceo peter france resigns aeni swings to profit on output rise oils rally asantander profit rises upbeat on banco popular abnp paribas profit falls but beats views abt earnings fall on higher costs backs guidance aair franceklm profit rises on higher airfares loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  michael j pellini md  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in michael j pellini md chairman of the board at foundation medicine inc view full profile are you michael j pellini md claim your profile   sign up for equilar atlas and view michael j pellini mds full profile with equilar atlas you can identify corporate executives in michael j pellini mds network and community follow changes in michael j pellini mds employment and moneyinmotion connect with michael j pellini md through your network of contacts michael j pellini mds executive work history current chairman of the board foundation medicine inc past to view michael j pellini mds complete executive work history sign up now age      michael j pellini mds biography michael pellini md has served as a member of our board of directors since may  and as our chairman since february  he served as our chief executive officer from may  until february  and as our president from may  until march  dr pellini joined us from clarient inc clarient a general electric healthcare company which was acquired by neogenomics inc nasdaq neo in  where he held the position of president and chief operating officer from april  to april  and served on its board of directors from may  to april  dr pellini served as vice president life sciences at safeguard scienti  read more michael pellini md has served as a member of our board of directors since may  and as our chairman since february  he served as our chief executive officer from may  until february  and as our president from may  until march  dr pellini joined us from clarient inc clarient a general electric healthcare company which was acquired by neogenomics inc nasdaq neo in  where he held the position of president and chief operating officer from april  to april  and served on its board of directors from may  to april  dr pellini served as vice president life sciences at safeguard scientifics inc nyse sfe a private equity and venture capital firm specializing in expansion financings growth capital management buyouts recapitalizations industry consolidations corporate spinouts growth stage and early stage financings from march  to april  and as part of this role was detailed to clarient beginning in july  dr pellini received a ba from boston college an mba from drexel university and an md from jefferson medical college now the sidney kimmel medical college of thomas jefferson university dr pellini currently serves on the board of directors of tango therapeutics inc dr pellinis qualifications to sit on our board of directors include his extensive leadership executive managerial business and diagnostic company experience including as our former chief executive officer along with his years of industry experience in the development and commercialization of pharmaceutical products source foundation medicine inc on    sign up for equilar atlas and view michael j pellini mds full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like michael j pellini md more specifically youll be able to identify corporate executives in michael j pellini mds network and community follow changes in michael j pellini mds employment and moneyinmotion connect with michael j pellini md through your network of conections view full profile   search for over  executive profiles bio example michael j pellini md michael j pellini mds connections  sign up now to view michael j pellini mds  connections » james a datin former executive vice president and managing director life sciences safeguard scientifics inc jerry l johnson board member bryn mawr bank corporation calvin h knowlton chief executive officer and chairman of the board tabula rasa healthcare inc brook h byers board member pacific biosciences of california inc stephen t zarrilli dir president and chief executive officer safeguard scientifics inc ronald a andrews former president genetic and medical sciences life technologies corporation krishna yeshwant former board member foundation medicine inc raymond j land chairman of the board bioamber inc michael r dougherty board member aviragen therapeutics inc vincent a miller chief medical officer foundation medicine inc popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith carl g annessa evp and coo hornbeck offshore services inc elon r musk ceo and chairman tesla michael c montgomery board member nmi holdings inc × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login �  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   michael pellini  foundation medicine inc  zoominfocom roche plans  billion collaboration with foundation medicine breast cancermultiple myelomalung cancerimmunooncology newsgynecologic oncologygastrointestinal cancercolorectal cancerovarian cancerprostate cancerneoadjuvant herbrain cancerbone metastasesbusiness managementcar tcell therapychronic lymphocytic leukemiahead  neck cancershematologic malignanciesimmunotherapy in gu cancersimmunotherapy in lung cancerimmunotherapy in melanomakidney cancerleukemiamantle cell lymphomamelanoma  skin cancermetastatic castrationresistant prostate cancernonhodgkins lymphomaoncology nursing newspatient resourcesprecision medicine in oncology®soft tissue sarcomaspecial reports in personalized cancer caresupportive careurologic oncology online continuing education activitiesinteractive publications select a topic current view all specialties ▲ education ▲ education ▼ register  login conference coveragenewsnetworkonclive tvpeer exchangeonclive insights specialty topicscurrently viewingall specialtiesbreast cancermultiple myelomalung cancerimmunooncology newsgynecologic oncologygastrointestinal cancercolorectal cancerovarian cancerprostate cancerneoadjuvant hermore  web exclusives  roche plans  billion collaboration with foundation medicine silas inman silasinman published online monday jan   daniel oday ceo roche has announced plans to acquire a majority stake in the molecular testing company foundation medicine for  billion launching a partnership that will focus on the development of personalized medicine for patients with cancerthe majority stake a minimum of  and a maximum of  will be gained through the acquisition of  million shares for  million and an additional  million in newly issued shares for  million additionally under the newly formed partnership roche will sponsor broad research  development activities conducted by foundation medicine with the potential of more than  million in research funding“we are very pleased to enter into this collaboration with foundation medicine which has the potential to improve both the development of medicines and patient care” daniel o’day chief operating officer of roche pharma said in a statement “by combining foundation medicine’s pioneering approach to genomics and molecular information with roche’s expertise in the field of oncology we can bring personalized healthcare in oncology to the next level”the foundation medicine board of directors unanimously approved the transaction however it is still subject to shareholder approval at this point three shareholders who own  of the companys equity have supported the agreement third rock ventures kleiner perkins caufield  byers and google venturesthe deal is expected to close in the second quarter of roches investment in foundation medicine arrives approximately  months after the companys initial public offering which occurred on september   in  the company announced that it had secured  million in total revenue representing a  increase over foundation medicine’s success is largely predicated upon its two full genomic profile assays foundationone and foundationone heme these tests utilize nextgeneration sequencing to identify actionable molecular alterations in a patients tumor in  physicians ordered  foundationone tests a  increase over “the rapid revenue growth in  was driven by progress across the three key pillars of our business specifically the continued adoption of comprehensive genomic profiling by oncologists in both the academic and community setting an increase in demand from our pharmaceutical partners for clinical trial support and expanded access to our molecular information platform” michael j pellini md who will continue to lead foundation medicine as president and ceo said in a statementthe foundationone heme test was first introduced in december  the test is billed as an aid in identifying therapy for leukemia lymphoma and myeloma and also sarcomas and pediatric cancersthrough the collaboration roche plans to broaden the reach of the foundation medicine tests roche will obtain rights outside of the united states to existing and future foundation medicine products within the united states roche will focus on medical education as it relates to the novel tests“we are excited to announce this strategic collaboration with roche which will help accelerate our business and importantly represents significant potential for individuals with cancer around the world said pelliniat this time foundation medicine maintains a number of partnerships with a variety of biotech companies these agreements will not be impacted by the roche collaboration pellini said“the structure of our agreement with roche also allows us to maintain the entrepreneurial spirit at foundation medicine and ensures that our business model network of partnerships and objectives are not altered  view conference coverage world congress on gi cancerth european postchicago melanoma  skin cancer meeting state of the science summit on melanoma and immunooncology european hematology association congress online cme activities titleexpiration datecme creditscancer summaries and commentaries™ update from chicago advances in the treatment of genitourinary cancersjul  cancer summaries and commentaries™ update from chicago advances in the treatment of breast cancerjul   publications covering every angle of oncology practice click a cover below to view more external resources mjh associates american journal of managed care cure md magazine oncology nursing news pharmacy times physicians education resource physicians money digest specialty pharmacy times targetedonc onclive resources articles blogs conference coverage onclive tv peer exchange publications specialties web exclusives about us advertise advisory board careers contact us forgot password press releases privacy policy terms  conditions   intellisphere llc  clarke drive suite  cranbury nj  p  f  copyright onclive  intellisphere llc all rights reserved   roche plans  billion collaboration with foundation medicine breast cancermultiple myelomalung cancerimmunooncology newsgynecologic oncologygastrointestinal cancercolorectal cancerovarian cancerprostate cancerneoadjuvant herbrain cancerbone metastasesbusiness managementcar tcell therapychronic lymphocytic leukemiahead  neck cancershematologic malignanciesimmunotherapy in gu cancersimmunotherapy in lung cancerimmunotherapy in melanomakidney cancerleukemiamantle cell lymphomamelanoma  skin cancermetastatic castrationresistant prostate cancernonhodgkins lymphomaoncology nursing newspatient resourcesprecision medicine in oncology®soft tissue sarcomaspecial reports in personalized cancer caresupportive careurologic oncology online continuing education activitiesinteractive publications select a topic current view all specialties ▲ education ▲ education ▼ register  login conference coveragenewsnetworkonclive tvpeer exchangeonclive insights specialty topicscurrently viewingall specialtiesbreast cancermultiple myelomalung cancerimmunooncology newsgynecologic oncologygastrointestinal cancercolorectal cancerovarian cancerprostate cancerneoadjuvant hermore  web exclusives  roche plans  billion collaboration with foundation medicine silas inman silasinman published online monday jan   daniel oday ceo roche has announced plans to acquire a majority stake in the molecular testing company foundation medicine for  billion launching a partnership that will focus on the development of personalized medicine for patients with cancerthe majority stake a minimum of  and a maximum of  will be gained through the acquisition of  million shares for  million and an additional  million in newly issued shares for  million additionally under the newly formed partnership roche will sponsor broad research  development activities conducted by foundation medicine with the potential of more than  million in research funding“we are very pleased to enter into this collaboration with foundation medicine which has the potential to improve both the development of medicines and patient care” daniel o’day chief operating officer of roche pharma said in a statement “by combining foundation medicine’s pioneering approach to genomics and molecular information with roche’s expertise in the field of oncology we can bring personalized healthcare in oncology to the next level”the foundation medicine board of directors unanimously approved the transaction however it is still subject to shareholder approval at this point three shareholders who own  of the companys equity have supported the agreement third rock ventures kleiner perkins caufield  byers and google venturesthe deal is expected to close in the second quarter of roches investment in foundation medicine arrives approximately  months after the companys initial public offering which occurred on september   in  the company announced that it had secured  million in total revenue representing a  increase over foundation medicine’s success is largely predicated upon its two full genomic profile assays foundationone and foundationone heme these tests utilize nextgeneration sequencing to identify actionable molecular alterations in a patients tumor in  physicians ordered  foundationone tests a  increase over “the rapid revenue growth in  was driven by progress across the three key pillars of our business specifically the continued adoption of comprehensive genomic profiling by oncologists in both the academic and community setting an increase in demand from our pharmaceutical partners for clinical trial support and expanded access to our molecular information platform” michael j pellini md who will continue to lead foundation medicine as president and ceo said in a statementthe foundationone heme test was first introduced in december  the test is billed as an aid in identifying therapy for leukemia lymphoma and myeloma and also sarcomas and pediatric cancersthrough the collaboration roche plans to broaden the reach of the foundation medicine tests roche will obtain rights outside of the united states to existing and future foundation medicine products within the united states roche will focus on medical education as it relates to the novel tests“we are excited to announce this strategic collaboration with roche which will help accelerate our business and importantly represents significant potential for individuals with cancer around the world said pelliniat this time foundation medicine maintains a number of partnerships with a variety of biotech companies these agreements will not be impacted by the roche collaboration pellini said“the structure of our agreement with roche also allows us to maintain the entrepreneurial spirit at foundation medicine and ensures that our business model network of partnerships and objectives are not altered  view conference coverage world congress on gi cancerth european postchicago melanoma  skin cancer meeting state of the science summit on melanoma and immunooncology european hematology association congress online cme activities titleexpiration datecme creditscancer summaries and commentaries™ update from chicago advances in the treatment of genitourinary cancersjul  cancer summaries and commentaries™ update from chicago advances in the treatment of breast cancerjul   publications covering every angle of oncology practice click a cover below to view more external resources mjh associates american journal of managed care cure md magazine oncology nursing news pharmacy times physicians education resource physicians money digest specialty pharmacy times targetedonc onclive resources articles blogs conference coverage onclive tv peer exchange publications specialties web exclusives about us advertise advisory board careers contact us forgot password press releases privacy policy terms  conditions   intellisphere llc  clarke drive suite  cranbury nj  p  f  copyright onclive  intellisphere llc all rights reserved   michael j pellini md mba executive profile  biography  bloomberg july    am et biotechnology company overview of foundation medicine inc snapshotpeople  overviewboard memberscommittees executive profile michael j pellini md mbachairman foundation medicine incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationshipsas of fiscal year  background dr michael j pellini also known as mike md mba served as the chief executive officer at foundation medicine inc since may   until february   dr pellini previously served as chief operating officer at plus diagnostics inc he served as president of foundation medicine inc since may   until march  he served as president and chief operating officer at clarient inc he served as vice president of life sciences at safeguard scientifics  inc he serves as member of executive committee of the board of trustees at coriell institute for medical research the he serves as director and scientific advisory board member at cira discovery sciences inc he was entrepreneurinresidence at bioadvance he has been the chairman of foundation medicine inc since february   he served as a director at acelerate inc and genomics collaborative inc dr pellini holds a medical degree from jefferson medical college of thomas jefferson university in philadelphia a masters in business administration degree from drexel university in philadelphia and a bachelors degree ba in economics from boston college in massachpettsread full background corporate headquarters  second streetcambridge massachusetts united statesphone fax  board members memberships member of executive committee of the board of trusteescoriell institute for medical research thedirector and scientific advisory board membercira discovery sciences incpresentchairmanfoundation medicine inc education mba drexel universityba boston collegemd thomas jefferson universitymd thomas jefferson university school of medicine other affiliations safeguard scientifics incclarient incgenomics collaborative incdrexel universityboston collegethomas jefferson universityplus diagnostics incbioadvancecoriell institute for medical research thecira discovery sciences incacelerate incthomas jefferson university school of medicine annual compensation salarytotal annual compensation stocks options restricted stock awardsall other compensationexercisable optionsexercisable options valuetotal value of optionstotal number of options total compensation total annual cash compensationtotal short term compensationother long term compensationtotal calculated compensation request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationnamepositioncompanycompensationelazar rabbani phdcofounder chairman of the board chief executive officer and secretaryenzo biochem inckdouglas m vanoort chairman of the board  ceoneogenomics inckkimberly j popovits chairman chief executive officer and presidentgenomic health inckr bradley gray president ceo  directornanostring technologies inckpatrick soonshiong md frcs c facsceo chairman of the board  foundernanthealth inccompensation as of fiscal year  sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact foundation medicine inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close foundation medicine enters strategic collaboration with roche in the field of molecular information in oncology — kleiner perkins caufield byers × × all articles read next share share on facebook share on twitter share on linkedin article foundation medicine enters strategic collaboration with roche in the field of molecular information in oncology thursday january   jan   share on facebook share on twitter share on linkedin —collaboration leverages both companies’ strengths to advance the progress of personalized treatments for patients with cancer— roche to acquire a majority interest in foundation medicine of up to  on a fully diluted basis through a tender and acquisition of newly issued shares roche will tender for approximately  million foundation medicine shares at usd  per share with an aggregate tender value of approximately usd  million roche will also invest usd  million in foundation medicine by acquiring  million newly issued shares at usd  per share partnership includes both a broad rd collaboration with the potential for more than usd  million funding by roche to accelerate foundation medicine’s new product development initiatives optimize treatments for oncology patients and better design and understand the results of clinical trials based on molecular information as well as commercial collaboration agreements aimed at expanding the global sales efforts for foundation medicine’s current and future products michael j pellini md foundation medicine’s president and ceo will continue to lead the company postclosing along with foundation medicine’s current management team company will maintain operational independence roche to obtain minority representation on the expanded foundation medicine board of directors roche and foundation medicine boards of directors have unanimously approved the transaction cambridge mass—business wire— foundation medicine inc nasdaqfmi and roche six ro rog otcqx rhhby announced today that they will enter into a broad strategic collaboration to further advance foundation medicine’s marketleading position in molecular information and genomic analysis while providing roche a unique opportunity to optimize the identification and development of novel treatment options for cancer patients “we are very pleased to enter into this collaboration with foundation medicine which has the potential to improve both the development of medicines and patient care” said daniel o’day chief operating officer of roche pharma “by combining foundation medicine’s pioneering approach to genomics and molecular information with roche’s expertise in the field of oncology we can bring personalized healthcare in oncology to the next level” the emerging field of molecular information and genomic analysis will play an increasingly important role for future medicines and diagnostic solutions in particular for cancer patients foundation medicine supports physicians by providing comprehensive molecular information to characterize a tumor that is being matched with approved targeted therapy options and novel treatments in development understanding the comprehensive genomic profile of a patient’s disease will enable better personalized healthcare solutions to optimize treatment outcomes for patients with cancer “we are excited to announce this strategic collaboration with roche which will help accelerate our business and importantly represents significant potential for individuals with cancer around the world we believe that putting molecular information at the center of cancer care will help transform the delivery of care for patients and speed the pace of drug discovery and development” said dr pellini “the structure of our agreement with roche also allows us to maintain the entrepreneurial spirit at foundation medicine and ensures that our business model network of partnerships and objectives are not altered” novel approaches to rd product development and commercialization under the terms of the rd collaboration agreement roche is committing to rd funding of potentially more than usd  million for a minimum of five years and will contribute its expertise and breadth in oncology foundation medicine will continue to operate independently and will contribute its experience in the development of comprehensive genomic profiling tests for oncology the initial focus of the rd collaboration will be on developing genomic profile tests for cancer immunotherapies and for continuous bloodbased monitoring roche will be able to utilize foundation medicine’s proprietary molecular information platform to standardize clinical trial testing this aspect of the relationship is designed to enable comparability of clinical trial results for rd purposes and ultimately in the clinic foundation medicine’s pharmaceutical services business will not be impacted and could be enhanced as its capabilities increase with the investments and experience in working with roche as a customer the rd collaboration and foundation medicine’s current and future tests are expected to deliver insights to support development of combination therapies novel targets more accurate patient population identification and inclusion in clinical trials and next generation companion diagnostics the intention is to improve decision making and support optimization of patient care as oncology management becomes more complex in addition to the rd collaboration both parties also agreed to a commercial collaboration agreement designed to broaden foundation medicine’s position across clinical and molecular information markets specifically roche will obtain rights exus under the foundation medicine brand to existing foundation medicine products as well as to future codeveloped products in the us roche will engage its medical education team in providing medical information to pathologists the collaboration agreements will become effective upon the completion of roche’s direct investment in foundation medicine and the tender offer as described below transaction structure and governance under the terms of the contemplated transaction roche will invest usd  million in foundation medicine at a per share issuance price of usd   million shares to fund its operations and development in addition roche will commence a tender offer at a per share price of usd  which when combined with roche’s direct investment in foundation medicine will result in roche owning a minimum of  and a maximum of  of foundation medicine on a fully diluted basis the offer price constitutes a  premium over the closing price of last friday january   the completion of roche’s direct investment in foundation medicine and the successful outcome of the tender offer as well as the execution of the collaboration agreements are all crossconditional subject to foundation medicine shareholder approval clearance under the hartscottrodino antitrust improvements act and other customary closing conditions the transaction has been unanimously approved by the foundation medicine board of directors in addition third rock ventures kleiner perkins caufield  byers and google ventures three shareholders owning approximately  of foundation medicine equity combined have entered into a support agreement pursuant to which they have each committed to vote in favor of the transaction and to tender at least a majority of their shareholdings in the tender offer upon the closing foundation medicine’s board of directors will be increased to nine directors and will include three designees of roche including daniel o’day four existing independent directors of foundation medicine and michael pellini md will continue as directors and one new independent director will be added it is anticipated that alexis borisy will remain chairman the transaction is expected to close in the second quarter of  goldman sachs  co is acting as financial advisor to foundation medicine and goodwin procter llp is acting as legal counsel to foundation medicine citi is acting as financial advisor to roche and davis polk  wardwell llp is acting as legal counsel to roche url copied to clipboard recommended reading welcoming cloudhealth technologies google bmw and lowe’s invest in metal d printing startup lender better mortgage gets new kleiner perkins funding valuing firm at  million the dna of helix’s mission osisoft’s next chapter how farmers business network plans to disrupt big agra one farm at a time womens club the wing raises  million series a adds  locations vcs see opportunity in growing fertility market email this article subject foundation medicine enters strategic collaboration with roche in the field of molecular information in oncology separate multiple email addresses with a comma message send × sign up for ventured × sign up to receive our updates about trends in tech venture capital and startups director of foundation medicine nasdaqfmi pellini michael j sells  shares worth  stay connected latest posts in rss businessentertainmentfeatured newsfeatured press releasefinancehealthlifestylenationnon firstpageoriginalpress releasereviewshoppingsportsstockstechnologytravelworld latest comments in rss  empowerednews world news summary helping you stay informed business finance sports entertainment health technology travel shopping our writers about us privacy policy contact us advertise press releases director of foundation medicine nasdaqfmi pellini michael j sells  shares worth  according to foundation medicines most recent form  filing with the sec dated mar   pm company director pellini michael j disclosed selling  shares at a cost of  at the time of this transaction mar  this trade was worth  in total as of mar  pellini michael j now owns  shares in total worth about  for the last few recent trades made by foundation medicine nasdaqfmi director pellini michael j we have the following information sec form  filing mar  sold  shares at the rate of  per share total worth of this trade was  total number of shares owned as of mar  were  sec form  filing jan  sold  shares at the rate of  per share total worth of this trade was  total number of shares owned as of jan  were  sec form  filing jan  sold  shares at the rate of  per share total worth of this trade was  total number of shares owned as of jan  were  posted by george daniels on thursday march    pm edt all trademarks acknowledged filed under stocks comments and trackbacks closed follow responses rss  comments are closed latest news former  owner of internap corporation nasdaqinap park west asset management llc sells  shares worth  chairman of the board and ceo of salesforce nysecrm benioff marc sells  shares worth  pres sales  cust success of salesforce nysecrm martinez maria sells  shares worth  chief executive officer of salem media group nasdaqsalm atsinger edward g iii sells  shares worth  svp  chief accounting officer of cobiz financial inc nasdaqcobz dumlao troy sells  shares worth  evp  chief operations officer of cobiz financial inc nasdaqcobz dalton richard j sells  shares worth  ceo cobiz bank of cobiz financial inc nasdaqcobz page scott sells  shares worth  svp global sales of neophotonics corporation nysenptn sitler benjamin lee sells  shares worth  director of neophotonics corporation nysenptn sophie michael j sells  shares worth  president and ceo of skyworks solutions nasdaqswks griffin liam sells  shares worth  news categories business  stocks  entertainment  featured news  featured press release  finance  health  lifestyle  nation  non firstpage  original  press release  review  shopping  sports  technology  travel  world  featured press releases diatomite market analysis market size application analysis regional outlook competitive strategies and forecasts  plate bending rolls market professional survey report   global cold forging machine market by manufacturers regions type and application forecast to  camera drones market analysis  forecast  profiling dji innovations parrot sa denel soc automotive clutch market overview competitor analysis top manufacturers and forecast to  global animal nutrition chemicals market share supply analysis and forecast to  pulse width modulation market  – global industry size share analysis trend  future strategic planning seamless steel tube market segmented by product type top manufacturers by enduser industry geography trends  forecast  milk market global analysis   forecast research global fuel pump market  share trend segmentation and forecast to  business finance sports entertainment health technology travel shopping about us contact us privacy policy advertise press releases terms of service log in microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft robot check enter the characters you see below sorry we just need to make sure youre not a robot for best results please make sure your browser is accepting cookies type the characters you see in this image try different image continue shopping conditions of use privacy policy   amazoncom inc or its affiliates robot check enter the characters you see below sorry we just need to make sure youre not a robot for best results please make sure your browser is accepting cookies type the characters you see in this image try different image continue shopping conditions of use privacy policy   amazoncom inc or its affiliates robot check enter the characters you see below sorry we just need to make sure youre not a robot for best results please make sure your browser is accepting cookies type the characters you see in this image try different image continue shopping conditions of use privacy policy   amazoncom inc or its affiliates amazoncom amazon music unlimited interesting finds updated daily amazon try prime digital music all departments alexa skills amazon devices amazon video amazon warehouse deals appliances apps  games arts crafts  sewing automotive parts  accessories baby beauty  personal care books cds  vinyl cell phones  accessories clothing shoes  jewelry    women    men    girls    boys    baby collectibles  fine art computers courses credit and payment cards digital music electronics gift cards grocery  gourmet food handmade health household  baby care home  business services home  kitchen industrial  scientific kindle store luggage  travel gear luxury beauty magazine subscriptions movies  tv musical instruments office products patio lawn  garden pet supplies prime exclusive prime pantry software sports  outdoors tools  home improvement toys  games vehicles video games wine go departments en   hello sign inaccount  listssign inaccount  listsorderstry primecart your amazoncomtodays dealsgift cards  registrysellhelpdisability customer support amazon music unlimited prime music cds  vinyl download store open web player mp cart settings mo for prime members nonprime price month change or cancel anytime start your day free trial mo for prime members nonprime price month change or cancel anytime start your day free trial mo for prime members nonprime price month change or cancel anytime start your day free trial any song anywhere tens of millions of songs with new releases from todays most popular artists listen adfree with unlimited skips download for offline listening any song anywhere tens of millions of songs with new releases from todays most popular artists listen adfree with unlimited skips download for offline listening any song anywhere tens of millions of songs with new releases from todays most popular artists listen adfree with unlimited skips download for offline listening already using prime music upgrade to amazon music unlimited now to unlock tens of millions of songs including the hottest new releases only month or year  months for the price of  already using prime music upgrade to amazon music unlimited now to unlock tens of millions of songs including the hottest new releases only month or year  months for the price of  already using prime music upgrade to amazon music unlimited now to unlock tens of millions of songs including the hottest new releases only month or year  months for the price of  better with echo  just ask play your favorite music with innovative alexa voice controls exclusive to amazon music want amazon music unlimited just on your echo learn more better with echo  just ask play your favorite music with innovative alexa voice controls exclusive to amazon music want amazon music unlimited just on your echo learn more better with echo  just ask play your favorite music with innovative alexa voice controls exclusive to amazon music want amazon music unlimited just on your echo learn more choose the right amazon music plan for you learn more learn more learn more questions see our faq start free trial choose the right amazon music plan for you learn more learn more learn more questions see our faq start free trial choose the right amazon music plan for you learn more learn more learn more questions see our faq start free trial theres a problem loading this menu right now learn more about amazon prime get fast free shipping with amazon prime prime members enjoy free twoday shipping and exclusive access to music movies tv shows original audio series and kindle books  get started v michael pellini  wowcom  web results aol search skip over navigation search the web web images images reference reference we found michael pellini  searching for michael pellini ad · wwwspokeocom​michael pellini searching for michael pellini get phone  address pics  more social network search white pages directory search public records free people search searches related tomichael pellini mike pellini foundation medicine dr michael pellini mike pellini foundation medicine dr pelini akron ohio michael pelini md akron dr pellini web results michael pellini  linkedin httpswwwlinkedincominmichaelpelliniab view michael pellini’s professional profile on linkedin linkedin is the worlds largest business network helping professionals like michael pellini discover  michael mike pellini  bloombergcom httpswwwbloombergcomprofilespeople michael mike pellini is former chief executive officer at foundation medicine inc see michael j pellinis compensation career history education  memberships dr michael pelini md  akron oh  cardiology  clinical  wwwhealthgradescomphysiciandrmichaelpelinivqyd visit healthgrades for information on dr michael pelini md find phone  address information medical practice history affiliated hospitals and more michael pellini  massachusetts biotechnology council httpswwwmassbioorgaboutboardofdirectorsmichaelpellini dr pellini joined foundation medicine as president and chief executive officer in may  bringing a breadth of experience in life sciences and the clinical  michael pellini  whitepages wwwwhitepagescomnamemichaelpellini view phone address history email public records for the  people named michael pellini whitepages is the most trusted directory michael pellini profiles  facebook httpswwwfacebookcompublicmichaelpellini view the profiles of people named michael pellini join facebook to connect with michael pellini and others you may know facebook gives people the power michael pellini md  salarycom wwwsalarycommichaelpellinimdsalarybonusstockoptionsfor salary bonuses stock options stock awards and other compensation for michael pellini md chief executive officer at foundation medicine inc how much did michael  michael j pellini md  executive bio compensation  peopleequilarcombiomichaelpellinicoriellinstitutesalary view michael j pellini md chairman of the board at foundation medicine inc cambridge ma executive profile on equilar atlas to see current salary at  michael pellini president and chief executive officer  httpswwwvbprofilescompeoplemichaelpellinid curated profile of michael pellini president and chief executive officer foundation medicine including career history news and intelligence portfolio companies  mike pellini md michaelpellini  twitter httpstwittercommichaelpellini the latest tweets from mike pellini md michaelpellini unemployed chairman foundation medicine inc cambridge ma we found michael pellini  searching for michael pellini ad · wwwspokeocom​michael pellini searching for michael pellini get phone  address pics  more social network search white pages directory search public records free people search searches related tomichael pellini mike pellini foundation medicine dr michael pellini mike pellini foundation medicine dr pelini akron ohio michael pelini md akron dr pellini next answers foundation medicine development and rd activities foundation medicine also has business agreements with johnson  johnson and novartis the companys chief executive more raymond oconnor heston brother  short  careful what you wish for sleazy salesman short  dont come knocking elko policeman  charlie  just like heaven more list of people from mississauga entertainment gordon carton b  former mpp michael caruso b  ebel ice hockey player claire carverdias synchronized swimmer deanna more search the web  aol inc all rights reservedprivacy   terms of use   about our ads   preferences   contact us   powered by bing™ part of the aol search network